Drug Landscape ›
cardiac output changes with "nor-epinephrine" ›
Regulatory · United States
Marketing authorisations
FDA — authorised 19 November 1948
Application: NDA021381
Marketing authorisation holder: DENTSPLY PHARM
Status: approved
FDA — authorised 18 November 1965
Application: NDA021383
Marketing authorisation holder: DENTSPLY PHARM
Status: supplemented
FDA — authorised 20 December 1972
Application: ANDA083154
Marketing authorisation holder: ABBOTT
Status: approved
FDA — authorised 2 January 1973
Application: NDA017060
Marketing authorisation holder: TEVA BRANDED PHARM
Status: supplemented
FDA — authorised 7 December 2012
Application: NDA204200
Marketing authorisation holder: PH HEALTH
Status: supplemented
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 64,169
Most-reported reactions
Drug Ineffective — 13,084 reports (20.39%) Fatigue — 6,768 reports (10.55%) Headache — 6,684 reports (10.42%) Pain — 6,547 reports (10.2%) Nausea — 6,446 reports (10.05%) Off Label Use — 6,180 reports (9.63%) Dyspnoea — 5,923 reports (9.23%) Sinusitis — 4,309 reports (6.72%) Diarrhoea — 4,214 reports (6.57%) Dizziness — 4,014 reports (6.26%)
Source database →
cardiac output changes with "nor-epinephrine" in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is cardiac output changes with "nor-epinephrine" approved in United States?
Yes. FDA authorised it on 19 November 1948; FDA authorised it on 18 November 1965; FDA authorised it on 20 December 1972.
Who is the marketing authorisation holder for cardiac output changes with "nor-epinephrine" in United States?
DENTSPLY PHARM holds the US marketing authorisation.